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Abstract: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) serves as a guide to treat and manage dif-
ferent severity classes of patients with COPD. It was suggested that the five categories of FEV1 % predicted (GOLD 0–4), 
can be applied for selecting different therapeutic approaches. However, validation of these selective properties is very 
poor. To determine the relevance of the GOLD staging system for estimating the severity of clinical problems, GOLD 2 
(n=70) and GOLD 3 (n=65) patients were drawn from a prospective cohort of patients with COPD and evaluated cross-
sectionally by a newly developed Nijmegen Integral Assessment Framework (NIAF). The NIAF is a detailed assessment 
of a wide range of aspects of health status (HS). Significant, though small, differences were found in Static Lung Vol-
umes, Exercise Capacity, Subjective Pulmonary Complaints, Subjective Impairment, and Health-Related QoL, besides 
Airflow of course. Moreover, overlap between scores of these five HS sub-domains was substantial, indicating small 
clinical relevance for discernment. No significant differences were found in nine other aspects of HS. It is concluded that 
GOLD stages do not discriminate in any aspect of HS other than airflow obstruction, and therefore do not help the clini-
cian in deciding which treatment modalities are appropriate. 
INTRODUCTION 
 The GOLD classification for chronic obstructive pulmo-
nary disease (COPD) has been introduced in order to facili-
tate comparability of clinical studies, by stratifying patients 
according to severity of airflow limitation, measured as 
forced expiratory volume in 1 second as percentage of pre-
dicted (FEV1%) [1,2]. Severity classes of COPD can be used 
to tailor diagnostic and therapeutic interventions in the man-
agement of this large patient group. 
 Clearly, airflow obstruction is only one aspect of COPD. 
Other key pathophysiological aspects include hyperinflation, 
diminished exercise capacity, malnourishment, and de-
creased muscle strength. In addition, there are clinical mani-
festations such as dyspnoea, functional impairment in daily 
life, and quality of life. All these aspects are key components 
of health status (HS) [3-5]. 
 It is unclear to what extent GOLD stages discriminate in 
aspects of health status, other than airflow obstruction. One 
study showed a statistically significant difference only in St. 
George’s Respiratory Questionnaire (SGRQ) section impact 
and total score between GOLD 2 and 3 (previously desig-
nated as stages 2a and 2b), but not in the sections symptoms 
and activities [6]. Another study found higher exacerbation 
rates with increasing COPD severity stage (0-IV), but the 
correlation was weak (r=0.29) [7]. Other relationships be-
tween GOLD stages and aspects of health status have not 
been reported. 
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 In studies on the relationship between health status and 
GOLD staging, to date, only few aspects of health status 
were measured. The SGRQ is most frequently used, but as 
this instrument contains only three sections, at best three 
aspects of health status are measured. In a previous study we 
have developed and validated a conceptual framework of 
health status, the Nijmegen Integral Assessment Framework 
(NIAF) [8]. This framework provides a much more detailed 
definition of health status, and is much more formulated in 
terms of empirical observations than definitions found in the 
literature. The NIAF covers the following main domains of 
health status: Physiological Functioning, Complaints, Func-
tional Impairment, and Quality of Life. These four main 
domains were found to be subdivided into 15 more concrete 
and relatively independent sub-domains. In addition, the 
NIAF provides an integration of many existing tests and 
instruments, by indicating which aspect of health status is 
measured by each instrument. 
 The purpose of the present study was to evaluate the 
relevance of the GOLD classification in COPD to a broad 
spectrum of aspects of health status, as measured by the 
NIAF. We focused on GOLD stages 2 and 3, as these stages 
make up the major part of patients seen in primary and sec-
ondary care, and because previous studies have shown that 
GOLD stages discriminated in aspects of health status be-
tween these two stages, and not between other consecutive 
stages. 
METHODS 
Study Design and Recruitment of Patients 
 Cross-sectional data were collected from a prospective 
cohort of patients with COPD, who visited three outpatient 
pulmonary clinics for respiratory complaints. The clinics 
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consisted of one University Hospital (Radboud University 
Nijmegen Medical Centre, location Dekkerswald), a non-
academic teaching hospital (Rijnstate Hospital), and a 
smaller city-hospital (Maas Hospital). Patients were seen by 
pulmonologists, whether for reasons of follow-up or new 
referrals. All patients with an established diagnosis of COPD 
within GOLD stages 2 and 3 (FEV1 post-bronchodilation 
between 30-80% predicted), and in a stable condition, were 
selected by examination of the medical records by one of the 
authors (JM). Exclusion criteria were: co-morbidity (e.g. 
cardial, neurological, oncological, or diabetes mellitus), 
acute exacerbation of COPD within six weeks before enrol-
ment, participation in a pulmonary rehabilitation program 
within the last six months, or inability to speak Dutch. 
 The recruitment procedure resulted in 361 eligible pa-
tients (Fig. 1). Of them, 316 (88%) gave permission for a 
telephone call by one of the investigators (LD). One-
hundred-and-forty-eight patients did not consent with the 
study protocol for a variety of reasons, e.g. refusing cycle 
ergometry, travel problems, being too busy at work or at 
home, feeling too old. Of the remaining 168 patients, all of 
whom had given written informed consent, 156 belonged to 
GOLD stages 2 and 3. Twelve patients had to be classified 
into GOLD 1 or 4 on the basis of their baseline post-
bronchodilator spirometry (shortly after enrolment), which 
differed slightly from spirometric values observed during the 
recruitment procedure. Finally, 21 non-smokers, all with a 
clear history of asthma extending from childhood, were 
excluded, resulting in 135 smoking-related COPD patients. 
Subgroup analysis of these never smoking chronic asthmat-
ics revealed neither significant differences in scores of the 
sub-domains of health status, nor in demographic variables, 
as compared to the total group (results not shown). 
Measurements 
 Health Status was assessed by the Nijmegen Integral 
Assessment Framework, developed and validated in a previ-
ous study of our research group [8]. This framework covers 
the following main domains of Health Status: (I) Physiologi-
cal functioning, (II) Complaints, (III) Functional Impairment 
and (IV) Quality of Life. These main domains were shown to 
be subdivided into 15 different sub-domains. Each sub-
domain is measured by different existing tests and instru-
ments, and for each sub-domain a Sub-domainTotalScore 
was calculated. Reliability of the different sub-domains of 
the framework was adequate to excellent. See Appendix for 
details on instruments used for each sub-domain. 
I. Main Domain Physiological Functioning 
 Routine pulmonary function tests were performed includ-
ing transfer capacity for carbon monoxide (CO), maximal 
exercise capacity, respiratory and skeletal muscle function, 
and indices of body composition. Various parameters were 
 
Fig. (1). Flow chart of inclusion procedure of patient recruitment, with list of reasons for non-participation. 
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168 informed 
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protocol 
156 GOLD 2&3 12 GOLD 1 & 4 
21 never smokers 135 current or ex-
smokers 
   Flow chart of inclusion procedure 
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incorporated into one of the following six sub-domains: 
Airflow, Static lung volumes, Exercise capacity, Gas Ex-
change, Muscle Force, and Body Composition. Maximal 
ergometry consisted of a symptom limited, incremental bicy-
cle test. Patients cycled at a rate of 60 rpm. After a 3 minute 
reference phase, workload was increased each minute by 
10% of estimated maximum work capacity. Whenever major 
abnormalities developed during the test in ECG or O2 satura-
tions at pulse-oxymetry, the test was ended by the attending 
physician. The quadriceps leg pressure dynamometer was 
used to measure quadriceps force. Fat free mass index 
(FFMI) was derived from the standard formula using 
bioelectrical impedance measurement (Bodystat 1997). 
II. Main Domain Complaints 
 The sub-domains were measured by specific subscales of 
the following self-reported questionnaires: Physical Activity 
Rating Scale-Dyspnoea (PARS-D) [9], Dyspnoea Emotions 
Questionnaire (DEQ) [8], and Quality of Life for Respiratory 
Illness Questionnaire (QoLRIQ) [10]. 
III. Main Domain Functional Impairment 
 The following questionnaires were used: Sickness Impact 
Profile (SIP) [11, 12], Global Impairment (measuring gen-
eral subjective experienced functional impairment) [9], and 
Quality of Life for Respiratory Illness Questionnaire (QoL-
RIQ). In addition, an accelerometer was used to measure 
actual physical activity level in daily life [9]. This small 
electronic device is worn at the ankle for 10 consecutive 
days, 24 hours per day (except when taking a bath or when 
swimming). 
IV. Main Domain Quality of Life 
 The Satisfaction with Life Scale (SWLS) [13, 14], Symp-
tom Check List (SCL) [15], Beck Depression Inventory 
(BDI) [16], and specific questions concerning satisfaction 
with physical functioning, future, spouse, and social func-
tioning [8] were used. 
Statistical Analyses 
 Differences between GOLD 2 and 3 with respect to 
nominal variables were tested by  test. Differences in the 
Sub-domainTotalScores of the Nijmegen Integral Assess-
ment Framework between GOLD stages 2 and 3 were ana-
lyzed by t-tests. To avoid Type I error due to the large num-
ber of tests, the p-value was set at < 0.01 for all analyses. For 
Sub-domainTotalScores that reached significance, box-plots 
were produced to test the clinical relevance of the statistical 
difference found between GOLD stages 2 and 3. The larger 
the overlap between both stages, the less the clinical rele-
vance. As the GOLD classification represents a categorical 
system, with relatively arbitrary boundaries, additional 
analyses were performed using the non-categorized FEV1% 
predicted. For this purpose, Pearson correlation coefficients 
of FEV1% predicted with the Sub-domainTotalScores were 
calculated. 
RESULTS 
Patient Characteristics 
 The main characteristics describing the patient sample 
are presented in Table 1. No significant differences were 
found between patients in GOLD 2 and 3 concerning age, 
sex, body mass index (BMI), smoking status, and duration of 
a self-reported diagnosis of COPD. The same was true for 
inspiratory vital capacity (IVC)% predicted, TLC% pre-
dicted, and PaCO2% predicted. TLCO% predicted was signifi-
cantly different between the two GOLD stages. Obviously, 
FEV1% predicted and Tiffeneau index were significantly 
different, because the division into different GOLD stages is 
based on FEV1% predicted. The number of patients in each 
group was equally distributed. 
Table 1. Anthropometric, Basic Pulmonary Function, and 
Demographic Data of the Study Sample 
 
Variable 
 (N=70)  
GOLD 2  
GOLD 3  
(N=65) 
Sex  Male  57 54 
Age  yrs  64.3 (10.2)  64.7 (8.3) 
BMI  kg/m  26.5 (3.8)  24.8 (4.0) 
IVC  %pred  94.5 (15.2)  90.1 (14.2) 
FEV1  %pred  61.0 (7.1)  40.9 (5.2) 
Tiffeneau %pred  50.0 (8.0)  35.0 (8.0) 
TLC %pred  100.9 (16.6)  106.0 (14.7) 
TLCO %pred  73.7 (21.5)  59.4 (22.3) 
PaO2 rest, kPa  11.1 (1.3)  10.6 (1.3) 
PaCO2rest, kPa  5.1 (0.5)  5.2 (0.5) 
Smoking status 
 current smoking 
 quit 
 
22 
48 
 
18 
47 
Self-reported COPD 
diagnosis, yrs. 
 < 1yr. 
 1 – 10 yrs. 
 > 10 yrs.  
 
12 
28 
30 
 
5 
30 
30 
Note: BMI= body mass index; IVC %pred= inspiratory vital capacity as percentage of 
predicted; FEV1 %pred= forced expiratory volume in one second as percentage of 
predicted; Tiffeneau %pred= FEV1/IVC as percentage of predicted. TLC %pred= total 
lung capacity as percentage of predicted; TLCO %pred= lung transfer capacity for 
carbon monoxide as percentage of predicted. Data are presented as N, or mean (SD). 
 
Sub-Domains of Health Status in Relation to GOLD 2 
and 3 
 Data of pulmonary function at rest and during maximal 
cycle ergometry, muscle function, and body composition are 
summarized by the six sub-domains of Physiological Function-
ing, and are shown in Table 2. Regarding FFMI, all values 
were in the normal range (> 16 kg/m for males and > 15 kg/m 
for females), although the mean value of females in GOLD 3 
hardly exceeded the lower limit of normal. Results on the sub-
domains of the main domains Complaints, Functional Impair-
ment, and Quality of Life are presented in Table 3. 
 Though a clear difference existed between GOLD 2 and 
3 regarding the sub-domain Airflow, differences in the other 
Sub-domainTotalScores were small or absent. Statistical 
significant differences were only found in five out of the 
other 14 sub-domains: Static lung volumes, Exercise capac-
ity, Subjective Pulmonary Complaints, Subjective Impair-
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ment, and Health-Related QoL. The sub-domain Gas Ex-
change (Table 2) lacks a Sub-domainTotalScore, as the two 
composing variables were not linear in distribution. Box-
plots (Fig. 2) show that considerable overlap existed between 
GOLD stage 2 and 3 for all five sub-domains that reached 
statistical significance. 
Table 2. Health Status Main Domain (I) Physiological Func-
tioning. Sub-Domain Total Scores (Mean (SD)) are 
Presented with p-Values for Difference Between 
GOLD Stage 2 and 3 and Values of Individual Pa-
rameters Composing Each Sub-Domain. Higher 
Scores of Sub-Domain Total Scores Indicate Worse 
Condition 
 
GOLD 2 GOLD 3 
 
Mean (SD) Mean (SD) 
p-Value 
T-Test 
Airflow 
FEV1 %pred 
MEF50 %pred 
VE max %pred 
762.7 (22.8) 
61.0 (7.1) 
24.7 (9.7) 
80.0 (15.7) 
812.7 (21.8) 
40.9 (5.2) 
13.1 (5.2) 
93.2 (22.1)  
 < .001 
Static lung volumes 
TLC %pred 
RV %pred 
145.6 (28.4) 
100.9 (16.6) 
120.3 (33.0) 
159.8 (26.3) 
106.0 (14.7) 
142.6 (33.2) 
 .003 
Exercise Capacity 
HRmax %pred 
VO2max%pred 
TLCO %pred 
Delta BE (kPa) 
444.5 (42.7) 
86.2 (13.8) 
77.9 (19.1) 
73.7 (21.5) 
-7.0 (2.8) 
478.5 (34.2) 
82.0 (11.9) 
63.2 (13.0) 
59.4 (22.3) 
- 5.5 (2.2) 
 < .001 
Gas Exchange: 
 (A-a)DO2 (kPa) 
 PaCO2 (kPa) 
 
0.96 (1.4) 
0.32 (0.5) 
 
1.14 (1.2) 
0.52 (0.5) 
 
.417 
.017 
Muscle Force 
Pi max %pred 
Pe max %pred 
Leg force %pred 
208.2 (34.0) 
114.9 (35.6) 
79.1 (23.2) 
83.4 (23.4) 
210.6 (33.7) 
107.9 (32.0) 
80.2 (23.8) 
83.2 (24.5) 
 .675 
Body Composition 
BMI (kg/m) 
FFMI (kg/m ) 
males 
females 
861.9 (27.2) 
26.5 (3.8) 
 
18.29 (1.8) 
15.88 (1.9) 
872.2 (28.0) 
24.8 (4.0) 
 
17.69 (1.8) 
15.08 (1.5) 
 .032 
Note: Delta BE= change in Base Excess during exercise test;  (A-a)DO2 (kPa)= change 
in (A-a)DO2 during exercise test; PaCO2 (kPa): change in PaCO2 during exercise test 
calculated as value at maximum exercise minus value at rest; FFMI : fat free mass 
index; values for males and females separately, taking into account different lower 
limits of normal. p < .01 is considered statistically significant and is displayed in bold. 
 
Sub-Domains of Health Status in Relation to FEV1% 
Predicted 
 Correlations between Sub-domainTotalScores and 
FEV1% predicted are presented in Table 4. Significant corre-
lations were found only for Airflow, Exercise capacity, and 
an index of Gas Exchange ( PaCO2). 
DISCUSSION 
 This is the first study that evaluated the relevance of the 
GOLD classification in relation to a broad range of aspects 
of health status in COPD. In the present study it was shown 
that the GOLD classification has no clinical relevance in 
aspects of health status other than airway obstruction. 
 The relevance of GOLD stages with respect to different 
aspects of health status (HS) was evaluated using the re-
cently developed Nijmegen Integral Assessment Framework 
(NIAF) of health status in COPD [8]. Most existing instru-
ments contain only three to five subscales, and thus measure 
only few aspects of HS. An integral assessment of HS there-
fore requires the use of multiple instruments. However, an 
evidence-based integration of existing instruments is lacking 
[17]. The NIAF covers the main domains Physiological 
Functioning, Complaints, Functional Impairment, and Qual-
ity of Life. We found that these four main domains were 
conceptually distinct, and were shown to be further subdi-
vided into 15 more concrete and homogeneous sub-domains. 
The NIAF has four key characteristics. First, it covers a 
broad range of aspects of health status relevant to COPD. 
Second, it integrates existing instruments by indicating 
which instruments measure the same sub-domain of HS, and 
it provides information on the validity of these instruments 
by indicating which sub-domain is actually measured. Third, 
all 15 sub-domains were shown to be relatively independent, 
which means that each sub-domain represents a unique as-
pect of the patient’s health status. Fourth, the sub-domains 
are measured by existing tests and instruments and for each 
sub-domain a single score is calculated. Taken together, the 
NIAF provides an empirical and detailed definition of health 
status, and allows a valid and integral assessment of 15 rela-
tively unrelated and therefore unique aspects of health status 
in COPD, expressed in only 15 scores. 
 We found significant differences between GOLD stage 2 
and stage 3 in only five of 15 sub-domains, other than airway 
obstruction. These were Static lung volumes, Exercise Capac-
ity, Subjective Pulmonary Complaints, Subjective Impairment, 
and Health-Related QoL. Considering the large overlap in the 
scores of these five sub-domains between both stages, the 
clinical relevance of these differences is small. With respect to 
the sub-domain Exercise Capacity, significant but minor cor-
relations with FEV1% predicted were reported by several 
authors, based mostly on maximal oxygen consumption 
(VO2max), varying between .22 and .44 [18-20]. In the present 
study the sub-domain Exercise Capacity contained three other 
factors in addition to VO2max, but we found a similar correla-
tion with FEV1% predicted (r= .38). Hyperinflation commonly 
occurs in conjunction with decreasing FEV1, but empirical 
studies on this issue are lacking. The correlation of the sub-
domains Static Lung Volumes and FEV1% predicted was low 
(r=-.22) and not statistically significant, indicating low shared 
variance. With respect to the main domain Complaints, there 
was a significant difference between both stages in sub-
domain Subjective Pulmonary Complaints, but not in the sub-
domains Dyspnoea Emotions and Dyspnoea Expected. With 
respect to the main domain Functional Impairment, GOLD 
discriminated in the sub-domain Subjective Impairment, but 
not in the sub-domains Behavioural Impairment and Actual 
Physical Activity. Concerning the main domain Quality of 
Life, GOLD stages discriminated only in the sub-domain 
Health-Related QoL. 
 Poor associations between airflow obstruction and other 
pathophysiological parameters, complaints, functional im-
pairment, and quality of life have been reported by many 
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studies [17, 20-27], but little research has been done on the 
clinical relevance of the GOLD classification system in rela-
tion to these different aspects of health status. A low correla-
tion (r=0.29) was reported between GOLD staging and num-
ber of hospital readmissions for exacerbations [7]. Antonelli-
Incalzi et al. [6] found significant differences between 
GOLD stages regarding the St. George’s Respiratory Ques-
tionnaire (SGRQ). However, no significant differences were 
found for the 6-minute walk distance, quality of sleep, and 
cognitive and affective status. Also, the differences in the 
SGRQ scores were only found for some subscales of the 
SGRQ, and only between stages 2 and 3 (previously stages 
2a and 2b). Similar to the present study, the authors found 
large variability within all GOLD stages, resulting in major 
overlap in scores between consecutive stages. Strikingly, this 
study also demonstrated substantial problems in health status 
in patients with COPD with GOLD stage 0 and stage 1. The 
authors concluded that health status cannot be inferred from 
GOLD stage. 
 Two studies used criteria for disease staging similar to 
GOLD. Ferrer and colleagues [28] found low to moderate 
correlations of the SGRQ subscales with COPD stages ac-
cording to the American Thoracic Society (ATS) guidelines 
(r=.27 to .51). This relationship was stronger in patients 
without co-morbidity, as compared to patients with co-
morbidity (r=.68 versus .40, respectively). These authors 
also reported a large overlap in scores between the ATS 
stages and substantial health status problems in patients with 
mild disease severity. Hajiro et al. used British Thoracic 
Society (BTS) staging criteria [29]. They found significant 
differences between moderate and severe COPD on all sub-
scales of the SGRQ and VO2max. Between mild and moderate 
COPD they only found significant differences on the sub-
scale activity and the total score of the SGRQ. Several pul-
monary function parameters, dyspnoea, anxiety, and depres-
sion were not significantly different between any stage. 
 Results of the present study and previous studies show 
that a classification system based on the severity of airflow  
 
obstruction has no relevance with respect to aspects of health 
status other than airflow obstruction. In only a few aspects of 
health status significant relationships were found, but con-
sidering the major overlap in scores between consecutive 
stages these differences have little clinical relevance. We 
explicitly would discard staging systems based on only one 
aspect of health status in favour of assessment incorporating 
multiple aspects of health status. 
 This conclusion is not surprising, because many studies 
have shown that airflow obstruction (the parameter on which 
the GOLD stages are based) is poorly related to other patho-
physiological processes, functional impairment, complaints, 
and quality of life. In addition, previously, we found that the 
15 sub-domains of HS represented by the NIAF are rela-
tively independent [8]. This means that scores on a particular 
sub-domain, such as airflow, do not predict scores on other 
sub-domains. 
 Some methodological considerations should be dis-
cussed. First, we focused on patients with GOLD stages 2 
and 3, as these patients constitute the most part of patients 
seen in medical care, and because in a previous study it was 
shown that GOLD stages discriminated in aspects of health 
status between these stages, and not between other consecu-
tive stages [6]. Second, we excluded primary co-morbidity to 
exclude its confounding effect, which was reported in a 
study on the relationship between ATS classification and 
health status [28]. In that study, also a relationship between 
disease stage and the SGRQ was found. This relationship 
was most pronounced in patients without co-morbidity. 
Thus, if any differences between GOLD stages are present, 
these would have been found in the present sample where 
co-morbidity was excluded. 
 The present findings have important implications for 
clinical practice and research. The GOLD classification was 
designed to create more homogeneous subgroups for re-
search purposes, and it was expected that this classification 
could guide diagnosis and treatment of COPD [1, 2]. Our 
findings show that GOLD staging is only clinically meaning- 
 
 
Table 3. Health Status (HS) Main Domains II Complaints, III Functional Impairment and IV Quality of Life. Sub-Domain Total 
Scores Mean (SD) for GOLD 2 and 3 and p-Values for Differences from T-Tests. Detailed Information on the Instruments 
that Constitute these Sub-Domains is Available in Appendix 1 
 
 GOLD 2 GOLD 3 Diff. GOLD 2 vs 3. (T-Test) 
 Mean (SD) Mean (SD) p Value 
II Complaints 
subjective pulmonary complaints 
dyspnoea emotions 
dyspnoea expected 
 
57.3 (19.2) 
40.1 (13.2) 
2.1 (0.9) 
 
69.2 (20.5) 
45.2 (12.1) 
2.5 (1.0) 
 
.001 
.023 
.032 
III Functional Impairment 
actual physical activity 
behavioural impairment 
subjective impairment 
 
177.3 (27.1) 
21.3 (16.2) 
98.3 (22.9) 
 
182.4 (30.3) 
27.8 (16.4) 
111.4 (24.7) 
 
.305 
.023 
.002 
IV Quality of Life 
general wellbeing 
Health-Related QoL 
satisfaction in social relations 
 
53.7 (12.1) 
19.1 (8.0) 
9.6 (8.1) 
 
56.4 (11.7) 
23.2 (9.1) 
10.1 (8.9) 
 
.190 
.006 
.703 
Note: Significant p-values are depicted in bold. 
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Fig. (2). Box plots of Sub-domainTotalScores (y-axis) which were significant in t-test, split by GOLD stage (x-axis). 
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ful with respect to airway obstruction, but not to any other 
aspect of health status, such as other physiological processes, 
complaints, functional impairment in daily life, and quality 
of life. The relative independence of the different sub-
domains of health status implies that treatment directed at 
only one aspect of HS, for example airflow obstruction, does 
not result in improvement in other aspects. Integral diagno-
sis, treatment, and management of COPD therefore should 
go beyond staging and management of airway obstruction 
alone, and should include additional and specific interven-
tions aimed at improving other aspects of health status as 
well. In order to tailor treatment to the needs of an individual 
patient, GOLD staging proves to be inadequate. What is 
needed is an integral assessment of all aspects of health 
status. 
 The key characteristic of the NIAF is that multiple, and 
relatively unique aspects of health status are integrated, 
which produces a more complete picture of the patient with 
COPD. The recently developed BODE index also is an ap-
proach in which different aspects of COPD are combined to 
yield a more complete picture of the patient. The BODE 
index (Body Mass Index, airway obstruction, dyspnoea, and 
exercise capacity) significantly better predicted mortality 
[30] and hospitalization [31], as compared to FEV1 alone. 
The difference between the BODE index and the NIAF is, 
that the former combines the different aspects into a single 
parameter. The NIAF, in contrast, produces 15 different 
scores. In clinical practice, this has the advantage of obtain-
ing a detailed picture of an individual patient, with respect to 
which aspects of health status are problematic, and which 
aspects are not. This enables the clinician to fine-tune treat-
ment to the needs of an individual patient. 
 In conclusion, GOLD staging only has clinical relevance 
with respect to airflow obstruction, and not to any other sub-
domain of HS. Therefore, the GOLD classification system is 
not useful in guiding treatment and management of COPD. 
Integral assessment of different aspects of health status is 
needed. The NIAF provides clinicians with a detailed picture 
of the patient’s health status, and therefore a guide to tailor 
treatment to the needs of the individual patient. 
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Table 4. Pearson Correlations of Subdomains of Health Status (HS) Main Domains Physiological Functioning, Complaints, Func-
tional Impairment, and Quality of Life (QoL) with FEV1% Predicted and p-Value 
 
Sub-Domains of Main Domains Pearson Corr. with FEV1 % pred. p-Value 
Main domain Physiological Functioning 
Airflow 
Static Lung Volumes 
Exercise Capacity 
Gas Exchange: 
 (A-a)DO2 
 PaCO2 
Muscle Strength 
Body Composition 
 
- .88 
- .22 
- .41 
 
- .16 
- .27 
-.03 
-.20 
 
<0.001 
.011 
<.001 
 
.068 
.002 
.755 
.018 
Main domain Complaints 
Subjective 
Dyspnoea Emotions 
Dyspnoea Expected 
 
-.20 
-.05 
-.13 
 
.019 
.607 
.144 
Main domain Functional Impairment 
Actual Physical Activity 
Behavioural 
Subjective 
 
-.08 
-.16 
-.19 
 
.371 
.065 
.032 
Main domain Quality of Life 
General Quality of Life 
Health-Related QoL 
Satisfaction with relationships 
 
-.02 
-.18 
.02 
 
.835 
.042 
.850 
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Appendix 1 
List of instruments used to measure the HS main domains and sub-domains with description of included 
subscales.  
 
Main domain (bold) 
      Sub-domains (plain) 
Parameters  
Physiological Functioning   
     Airflow 
     Hyperinflation 
     Exercise capacity 
     Gas Exchange 
 
     Muscle Force 
     Body Composition 
FEV1%, MEF50%, VE% 
TLC%, RV% 
VO2%, TLCO%, BE-Delta, HRmax% 
 (A-a)DO2 
 PaCO2 
Pi  max %, Pe max %, Leg force % 
BMI  kg/m, FFMI  kg/m  
 
 Instrument Subscale 
Complaints   
     Subjective Pulmonary 
     Complaints 
Physical activity rating scale-
Dyspnoea 
 
 
Dyspnoea Emotions Questionnaire 
Quality of Life for Respiratory Illness 
questionnaire 
global activities 
global burden 
specific activities 
dyspnoea subjective 
breathing problems 
     Dyspnoea Emotions Dyspnoea Emotions Questionnaire frustration 
mood 
anxiety 
     Expected Dyspnoea  Physical activity rating scale-
Dyspnoea 
expected dyspnoea 
 
Functional impairment   
     Actual physical activity Accelerometer    
     Behavioural impairment Sickness impact profile 
 
body care & move-
ments  
home management  
mobility  
ambulation  
     Subjective impairment Quality of Life for Respiratory Illness 
questionnaire 
Global Impairment 
Sickness impact profile 
 
general activities 
social activities 
total 
burden 
social interaction 
Quality of life   
     General QoL Satisfaction With Life Scale 
Symptom Checklist 
Beck Depression Inventory 
total 
anxiety 
primary care 
     Satisfaction Health Satisfaction-Physical 
Satisfaction-Future 
 
     Satisfaction Relations Satisfaction-Spouse 
Satisfaction-Social 
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